Geographic Atrophy

GATHER 2: Avacincaptad pegol slows geographic atrophy growth

The investigational geographic atrophy (GA) therapy avacincaptad pegol effectively slowed the rate of GA growth in patients with the disease, according to data from the Phase 3 GATHER 2 trial. This is the first time an investigation therapy in GA has achieved the 12-month prespecified, primary endpoint in phase 3...